OBI Pharma Market Cap ($191.11 Million)
Market Cap & Net Worth: OBI Pharma (4174)
OBI Pharma market cap. OBI Pharma (TWO:4174) has a market capitalization of $191.11 Million (NT$6.07 Billion) as of November 6, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #16530 globally and #799 in its home market, demonstrating a -11.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OBI Pharma's stock price NT$46.10 by its total outstanding shares 131580000 (131.58 Million). Also see OBI Pharma cash conversion from operations for how efficiently the company converts equity into cash flow.
OBI Pharma Market Cap History (2015–2026)
OBI Pharma market cap history from 2015 to 2026. Data shows change from $2.72 Billion to $191.11 Million (-17.76% CAGR). Check OBI Pharma (4174) share price today for real-time trading data and today's change.
OBI Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OBI Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 4174 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.91x
OBI Pharma's market cap is 1.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.18 Billion | $92.42 Million | -$1.11 Billion | 12.78x | N/A |
| 2017 | $623.90 Million | $376.00K | -$1.38 Billion | 1659.30x | N/A |
| 2018 | $648.77 Million | $13.34 Million | -$1.22 Billion | 48.64x | N/A |
| 2019 | $547.20 Million | $872.00K | -$1.44 Billion | 627.53x | N/A |
| 2020 | $576.22 Million | $140.89 Million | -$1.49 Billion | 4.09x | N/A |
| 2021 | $472.59 Million | $18.77 Million | -$1.72 Billion | 25.18x | N/A |
| 2022 | $286.45 Million | $4.71 Million | -$1.90 Billion | 60.81x | N/A |
| 2023 | $287.70 Million | $41.55 Million | -$1.27 Billion | 6.92x | N/A |
| 2024 | $242.51 Million | $62.68 Million | -$2.31 Billion | 3.87x | N/A |
| 2025 | $111.93 Million | $58.58 Million | -$2.05 Billion | 1.91x | N/A |
Competitor Companies of 4174 by Market Capitalization
Companies near OBI Pharma in the global market cap rankings as of November 6, 2026. Also see how large is OBI Pharma's balance sheet for a full breakdown of the balance sheet.
Key companies related to OBI Pharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of OBI Pharma (2015–2026)
Market capitalization of OBI Pharma from 2015 to today. Between 2015 and today, OBI Pharma's market cap moved from $2.72 Billion to $ 191.11 Million, with a yearly change of -17.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$191.11 Million | +70.74% |
| 2025 | NT$111.93 Million | -53.85% |
| 2024 | NT$242.51 Million | -15.71% |
| 2023 | NT$287.70 Million | +0.43% |
| 2022 | NT$286.45 Million | -39.39% |
| 2021 | NT$472.59 Million | -17.99% |
| 2020 | NT$576.22 Million | +5.30% |
| 2019 | NT$547.20 Million | -15.65% |
| 2018 | NT$648.77 Million | +3.99% |
| 2017 | NT$623.90 Million | -47.19% |
| 2016 | NT$1.18 Billion | -56.49% |
| 2015 | NT$2.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of OBI Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $191.11 Million USD |
| MoneyControl | $191.11 Million USD |
| MarketWatch | $191.11 Million USD |
| marketcap.company | $191.11 Million USD |
| Reuters | $191.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which ha… Read more